Last reviewed · How we verify
64Cu-DOTA-AE105
Somatostatin receptor targeting
Somatostatin receptor targeting Used for Neuroendocrine tumors.
At a glance
| Generic name | 64Cu-DOTA-AE105 |
|---|---|
| Sponsor | Curasight |
| Drug class | Somatostatin receptor targeting agent |
| Target | Somatostatin receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
64Cu-DOTA-AE105 is a radioligand that targets somatostatin receptors, which are overexpressed in certain types of tumors.
Approved indications
- Neuroendocrine tumors
Common side effects
Key clinical trials
- Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer (PHASE2)
- Evaluation of a New Radiotracer (64Cu-DOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 64Cu-DOTA-AE105 CI brief — competitive landscape report
- 64Cu-DOTA-AE105 updates RSS · CI watch RSS
- Curasight portfolio CI